

-----BEGIN PRIVACY-ENHANCED MESSAGE-----

Proc-Type: 2001,MIC-CLEAR

Originator-Name: keymaster@town.hall.org

Originator-Key-Asymmetric:

MFkwCgYEVQgBAQICAgADSwAwSAJBALeWW4xDV4i7+b6+UyPn5Rt0bb1cJ7VkACDq

pKb9/DClgTKIm081Cfoilvi9Wl4SODbR1+1waHHiGmeZ080dgLUCAwEAAQ==

MIC-Info: RSA-MD5,RSA,

bWazcY4ZnZdrqir009lXFtDuLuowzJJecXjeyjqGgKwPAlGft4WKRMujvpdfw8LF

LbiPlnFXm8N6ydKhby2qRw==

<IMS-DOCUMENT>0000892569-94-000085.txt : 19940331

<IMS-HEADER>0000892569-94-000085.hdr.sgm1 : 19940331

ACCESSION NUMBER: 0000892569-94-000085

CONFORMED SUBMISSION TYPE: 10-K

PUBLIC DOCUMENT COUNT: 8

CONFORMED PERIOD OF REPORT: 19931231

FILED AS OF DATE: 19940328

FILER:

COMPANY DATA:

COMPANY CONFORMED NAME:	ALLERGAN INC
CENTRAL INDEX KEY:	0000850693
STANDARD INDUSTRIAL CLASSIFICATION:	2834
IRS NUMBER:	951622442
STATE OF INCORPORATION:	DE
FISCAL YEAR END:	1231

FILING VALUES:

FORM TYPE:	10-K
SEC ACT:	34
SEC FILE NUMBER:	001-10269
FILM NUMBER:	94518114

BUSINESS ADDRESS:

STREET 1:	2525 DUPONT DR
CITY:	IRVINE
STATE:	CA
ZIP:	92715
BUSINESS PHONE:	7147524500

</IMS-HEADER>

<DOCUMENT>

<TYPE>10-K

<SEQUENCE>1

<DESCRIPTION>FORM 10-K

<TEXT>

<PAGE> 1

FORM 10-K  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF  
1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 1993

COMMISSION FILE NO.1-10269

&lt;TABLE&gt;

&lt;S&gt;

DELAWARE  
(State of Incorporation)

&lt;C&gt;

95-1622442  
(I.R.S. Employer  
Identification No.)

2525 DUPONT DRIVE  
IRVINE, CALIFORNIA  
(Address of principal executive offices)

92715-1599  
(Zip Code)

&lt;/TABLE&gt;

Registrant's telephone number: (714) 752-4500

Securities registered pursuant to Section 12(b) of the Act:

&lt;TABLE&gt;

&lt;S&gt;

Title of each class  
class registered

&lt;C&gt;

Name of each exchange on which each

Common Stock, \$0.01 par value  
Preferred Share Purchase Rights

New York Stock Exchange

&lt;/TABLE&gt;

Securities registered pursuant to Section 12(g) of the Act:

NONE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days.

Yes E No

The aggregate market value of the registrant's voting stock held by non-affiliates was approximately \$1,400,000,000 on February 28, 1994, based upon the closing price on the New York Stock Exchange on such date.

Common Stock outstanding as of February 28, 1994 - 63,904,229 shares

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [  ]

#### DOCUMENTS INCORPORATED BY REFERENCE

Parts I, II and IV incorporate certain information by reference from the registrant's Annual Report to Stockholders for the fiscal year ended December 31, 1993. With the exception of the sections of the Annual Report specifically incorporated by reference herein, the Annual Report is not deemed filed as part of this Report on Form 10-K.

Part III incorporates certain information by reference from the registrant's definitive proxy statement for the annual meeting of stockholders to be held on April 19, 1994, which proxy statement will be filed no later than 120 days after the close of the registrant's fiscal year ended December 31, 1993.

&lt;PAGE&gt; 2

#### TABLE OF CONTENTS

&lt;TABLE&gt;

&lt;CAPTION&gt;

Item	1.	Business.....	1
Item	2.	Properties.....	7
Item	3.	Legal Proceedings.....	8
Item	4.	Submission of Matters to a Vote of Security Holders.....	9
Item	I-A.	Executive Officers of Allergan, Inc. ....	9

## PART II

Item	5.	Market for Registrant's Common Equity and Related Stockholder Matters.....	12
Item	6.	Selected Financial Data.....	12
Item	7.	Management's Discussion and Analysis of Financial Condition and Results of Operations.....	12
Item	8.	Financial Statements and Supplementary Data.....	12
Item	9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.....	12

## PART III

Item	10.	Directors and Executive Officers of Allergan, Inc. ....	13
Item	11.	Executive Compensation.....	13
Item	12.	Security Ownership of Certain Beneficial Owners and Management.....	13
Item	13.	Certain Relationships and Related Transactions.....	13

## PART IV

Item	14.	Exhibits, Financial Statement Schedules and Reports on Form 8-K.....	14
------	-----	---	----

SIGNATURES.....	15
INDEX OF EXHIBITS.....	19
INDEPENDENT AUDITORS' REPORTS ON SCHEDULES.....	20
SCHEDULES.....	S-1
EXHIBITS.....	(Attached to this Report on Form 10-

K)  
</TABLE>  
<PAGE> 3

## PART I

## ITEM 1. BUSINESS

## GENERAL DEVELOPMENT OF BUSINESS

Allergan, Inc. ("Allergan" or the "Company") is a global provider of specialty therapeutic products principally in the areas of eye and skin care. Its worldwide consolidated revenues are generated by prescription and non-prescription pharmaceutical products in the areas of ophthalmology and dermatology, intraocular lenses (IOLs) and other ophthalmic surgical products, and contact lens care products.

Allergan was incorporated in California in 1948 and reincorporated in Delaware in 1977. In 1980, the Company was acquired by SmithKline Beckman Corporation (then known as "SmithKline Corporation" and herein "SmithKline"). The Company operated as a wholly-owned subsidiary of SmithKline from 1980 until July 27, 1989 when Allergan again became a stand-alone public company through a spin-off distribution by SmithKline.

During the fourth quarter of 1991, the Company divested its computer-based ophthalmic diagnostic instrument business, Allergan Humphrey. In November 1992, the Company sold its contact lens business in North and South America.

## ALLERGAN BUSINESSES

The following table sets forth, for the periods indicated, the net sales from continuing operations for each of the Company's specialty therapeutics businesses:

<TABLE>  
<CAPTION>

	Year Ended December 31		
	1993	1992	1991
	(in millions)		
<S>	<C>	<C>	<C>
Specialty Pharmaceuticals			
Eye Care	\$386.2	\$359.2	\$317.7
Skin Care	32.4	37.3	36.5
	-----	-----	-----
	418.6	396.5	354.2
Surgical	115.3	111.8	108.2
Optical Lens Care	325.0	322.4	299.3
	-----	-----	-----
TOTAL	\$858.9	\$830.7	\$761.7
	=====	=====	=====
Domestic			
	47.5%	47.9%	50.4%
International			
	52.5%	52.1%	49.6%

</TABLE>

The foregoing table does not include sales of discontinued operations. See Note 10 of Notes to Consolidated Financial Statements on page 46 of the 1993 Annual Report for further information concerning foreign and domestic operations.

## Specialty Pharmaceuticals

Allergan develops, manufactures and markets a broad range of prescription ophthalmic products designed to treat diseases and disorders of the eye, including glaucoma, inflammation,

1

<PAGE> 4

infection, allergy and ophthalmic muscle disorders. In addition, the specialty over-the-counter ("OTC") product line consists of products designed to treat ocular surface disease, including artificial tears and ocular decongestants.

The largest segment of the market for ophthalmic prescription drugs is for the treatment of glaucoma, a sight-threatening disease characterized by elevated intraocular pressure. For initial treatment of glaucoma, Allergan sells BETAGAN(R) ophthalmic solution, a beta adrenergic blocking agent; BETAGAN(R) is Allergan's largest selling pharmaceutical product. PROPINE(R) ophthalmic solution is the product which is used alone or in combination with other drugs when initial drug therapy for glaucoma becomes inadequate. Patent

is expected to develop in 1994. In 1993, Allergan entered into an agreement with Schein Pharmaceutical, Inc. whereby Schein will market generic versions of certain Allergan products that are off-patent in the U.S.; in March 1994, Schein began marketing a generic version of BETAGAN(R). Also in March 1994, Bausch & Lomb announced that it had obtained approval from the United States Food and Drug Administration ("FDA") to market a generic version of BETAGAN(R).

Allergan holds a major share of the U.S. market for ophthalmic steroids. The Company's PRED FORTE(R) product is widely prescribed to fight ocular inflammation.

In 1993, Allergan entered into a strategic alliance with Fisons Corporation to co-promote certain ophthalmic pharmaceuticals in the United States. The alliance currently involves Allergan's ACULAR(R) 1 ophthalmic solution for the relief of itch associated with seasonal allergic conjunctivitis. Later, under the terms of the alliance, co-promotion is planned to expand to include Fisons' OPTICROM(R) 2 ophthalmic solution and nedocromil sodium ophthalmic solution.

Allergan's specialty pharmaceuticals include BOTOX(R) (Botulinum Toxin Type A) purified neurotoxin complex for the treatment of certain neuromuscular disorders which are characterized by involuntary muscle contractions or spasms. BOTOX(R) purified neurotoxin complex is being marketed in the United States, Canada, Germany, France, Italy, New Zealand and a number of other countries for the treatment of blepharospasm (the uncontrollable abnormal contraction of the eyelid muscles which can force the eye closed) and strabismus (misalignment of the eyes) in people 12 years of age and over. In March 1991, an application was filed with United States FDA for approval of a nonophthalmic claim for an indication related to a neck and shoulder neuromuscular disorder known as cervical dystonia (torticollis). Allergan has been asked to provide supplemental clinical data to support the torticollis filing.

Building upon its strength in marketing to medical specialties and taking advantage of synergies in research and development, Allergan's skin care division (known as Allergan Herbert) develops, manufactures and markets a line of therapeutic skin care products primarily to dermatologists in the United States. Its product line includes GRIS-PEG(R) tablets, a systemic anti-fungal product, ELIMITE(R) cream for the treatment of scabies and NAFTIN(R), a topical anti-fungal gel and cream.

---

(1)ACULAR(R) is a registered trademark, which is licensed from Syntex (U.S.A.) Inc.

(2)OPTICROM(R) is a registered trademark of Fisons Corporation.

2

<PAGE> 5  
Surgical

Allergan's surgical division (known as Allergan Medical Optics or AMO) develops, manufactures and markets intraocular lenses (IOLs), surgically related pharmaceuticals, phacoemulsification equipment and other ophthalmic surgical products.

The largest segment of the surgical market is for the treatment of cataracts. IOLs are used to replace the natural lens of a cataract patient when it has become clouded. To meet the wide range of IOL products demanded by the market, Allergan currently offers a variety of models, including rigid

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.